MIRA Pharmaceuticals Announces Launch of Phase 2a Clinical Trial for Ketamir-2 After Demonstrating Superior Efficacy in Neuropathic Pain Models
Mira Pharmaceuticals Inc. has announced that its lead drug candidate, Ketamir-2, has demonstrated superior efficacy in preclinical neuropathic pain models compared to ketamine, gabapentin, and pregabalin. The findings, which have been accepted for publication in the journal Frontiers in Pharmacology, show that Ketamir-2 effectively restored sensory function and reversed pain behaviors. These results support Mira Pharmaceuticals' plan to submit a Phase 2a clinical trial protocol to the FDA by the fourth quarter of 2025, with the aim of initiating the study by year-end. Additionally, the company is exploring the potential of Ketamir-2 in other central nervous system indications, such as depression and anxiety. The global neuropathic pain market is projected to grow significantly, with North America accounting for a substantial share of the market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-023110), on August 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.